OABI 4.10 Stock Price OmniAb, Inc.
Range: | 3.56-6.715 | Vol Avg: | 414170 | Last Div: | 0 | Changes: | 0.07 |
Beta: | 0.44 | Cap: | 0.47B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Thu Sep 30 2021 | Empoloyees: | 106 |
CUSIP: | 68218J103 | CIK: | 0001846253 | ISIN: | US68218J1034 | Country: | US |
CEO: | Mr. Matthew W. Foehr | Website: | https://www.omniab.com |
OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.